Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $316.32 | 8 | 67.6% |
| Education | $151.31 | 3 | 32.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $130.00 | 2 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $126.81 | 3 | $0 (2023) |
| GlaxoSmithKline, LLC. | $111.19 | 1 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $57.20 | 3 | $0 (2024) |
| Celgene Corporation | $26.26 | 1 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $16.17 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $82.81 | 2 | Incyte Corporation ($65.00) |
| 2023 | $227.62 | 5 | AstraZeneca Pharmaceuticals LP ($115.05) |
| 2022 | $141.03 | 3 | GlaxoSmithKline, LLC. ($111.19) |
| 2021 | $16.17 | 1 | Merck Sharp & Dohme Corporation ($16.17) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/16/2024 | Incyte Corporation | — | Education | Cash or cash equivalent | $65.00 | General |
| 05/14/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $17.81 | General |
| Category: Oncology | ||||||
| 12/14/2023 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Education | In-kind items and services | $21.31 | General |
| Category: Hematology | ||||||
| 12/04/2023 | Incyte Corporation | — | Education | Cash or cash equivalent | $65.00 | General |
| 09/18/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $26.26 | General |
| Category: Hematology | ||||||
| 02/28/2023 | AstraZeneca Pharmaceuticals LP | EPANOVA (Drug) | Food and Beverage | In-kind items and services | $23.49 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/15/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $91.56 | General |
| Category: Oncology | ||||||
| 12/01/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $18.08 | General |
| 11/02/2022 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $111.19 | General |
| Category: ONCOLOGY | ||||||
| 06/09/2022 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $11.76 | General |
| Category: Oncology | ||||||
| 05/10/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $16.17 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 24 | 25 | $5,350 | $946.47 |
| 2022 | 1 | 12 | 14 | $2,920 | $510.11 |
| 2021 | 1 | 34 | 37 | $6,512 | $1,472 |
| 2020 | 1 | 69 | 80 | $13,976 | $2,628 |
All Medicare Procedures & Services
6 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 24 | 25 | $5,350 | $946.47 | 17.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 12 | 14 | $2,920 | $510.11 | 17.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 23 | 25 | $4,400 | $1,045 | 23.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 11 | 12 | $2,112 | $427.50 | 20.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 36 | 47 | $8,168 | $1,569 | 19.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 33 | 33 | $5,808 | $1,059 | 18.2% |
About Patricia Karwan, NP
Patricia Karwan, NP is a Nurse Practitioner healthcare provider based in Wakefield, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1700883568.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Patricia Karwan, NP has received a total of $467.63 in payments from pharmaceutical and medical device companies, with $82.81 received in 2024. These payments were reported across 11 transactions from 6 companies. The most common payment nature is "Food and Beverage" ($316.32).
As a Medicare-enrolled provider, Karwan has provided services to 139 Medicare beneficiaries, totaling 156 services with total Medicare billing of $5,557. Data is available for 4 years (2020–2023), covering 6 distinct procedure/service records.
Practice Information
- Specialty Nurse Practitioner
- Other Specialties Adult Health
- Location Wakefield, RI
- Active Since 07/07/2005
- Last Updated 11/05/2025
- Taxonomy Code 363L00000X
- Entity Type Individual
- NPI Number 1700883568
Products in Payments
- ZEJULA (Drug) $111.19
- IMFINZI (Biological) $103.32
- REBLOZYL (Biological) $47.57
- EPANOVA (Drug) $23.49
- OPDUALAG (Drug) $17.81
- KEYTRUDA (Biological) $16.17
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nurse Practitioner Doctors in Wakefield
Pamela Burlingame, Rnp, RNP
Nurse Practitioner — Payments: $185.02
Priscilla Durant, Np, NP
Nurse Practitioner — Payments: $123.94
Deborah Mchugh
Nurse Practitioner — Payments: $88.82
Mrs. Mollie Garrison, Ag-Acnp, AG-ACNP
Nurse Practitioner — Payments: $63.91
Kim Sylvestre, .Fnp-C, .FNP-C
Nurse Practitioner — Payments: $56.27
Lauren Perry, Np-C, NP-C
Nurse Practitioner — Payments: $23.04